Ellen Dewhurst

Cooley advised EyeBiotech Limited, a privately held, clinical-stage ophthalmology biotechnology company working to deliver a new generation of therapies for eye diseases, on the close of an extension to its Series A financing, bringing the total raised to date to $130 million.

Cooley advised Dimension as lead investor in Automata’s 33.1-million-pound Series C financing. Automata, an automation company helping life sciences rapidly innovate, diagnose and discover at scale, will use the funds to accelerate its rapid growth and industry presence across the US, UK, Europe, the Middle East and Africa. Partner Aaron Archer led the Cooley team advising Dimension, a first-of-its-kind firm partnering with founders at the intersection of technology and life sciences.

Cooley advised Quell Therapeutics, a leading T-regulatory (Treg) cell therapy biotech company based in London, on its exclusive collaboration with AstraZeneca.

Cooley advised Lightspeed Venture Partners on its investment in the $13 million Series A financing of Supercritical, a vetted carbon removal marketplace helping businesses reach net zero. Partner Aaron Archer led the Cooley team advising Lightspeed Venture Partners, a multistage venture capital firm focused on accelerating disruptive innovations and trends.